Month: August 2023

PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $100 million. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of VYJUVEKTM (beremagene geperpavec-svdt) for the treatment of recessive or dominant dystrophic epidermolysis bullosa (DEB) for patients 6 months of age and older. Under the Rare Pediatric Disease Priority Review Voucher Program, the FDA awards priority review vouchers to sponsors of rare pediatric disease product applications that meet certain...

Total revenues for the second quarter of 2023 of $10.8 million, representing an 83.6% increase over the comparable period in 2022 Gross profit grew to $2.4 million, up 84.8% from $1.3 million in the comparable period in 2022. Record backlog of $20 million as of August 21, 2023 Reaffirms its previous guidance of approximately $45 million in revenue for 2023NEW YORK, NY, Aug. 21, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Applied UV, Inc. (NASDAQ: AUVI), a leader in global food security, air quality, and intelligent building solutions today announced its financial results for the second quarter 2022. For the quarter, revenues were $10.8 million, increasing 83.6%, compared with $5.9 million in the second quarter of 2022. Gross profit for the second quarter of 2023 increased to $2.4 million, up 84.8%, compared with $1.3 million...

ALACHUA, Fla. and TAMPA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the successful first week of processing for Avance Nerve Graft at the newly opened Axogen Processing Center (APC), in Dayton, Ohio. “We are pleased to mark this significant milestone as we begin processing Avance Nerve Graft in our new APC facility,” commented Karen Zaderej, Axogen’s Chairman, CEO, and President. “The APC is a world-class tissue processing center that will support our Biologics License Application (BLA) submission in the first half of 2024 and our long-term growth. The BLA will further solidify our leadership in the nerve market, as we continue to provide surgeons and their patients with improved...

Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. “The Board of Directors and I offer our gratitude and best wishes to Daphne, who has made a far-reaching and positive impact on the financial strength...

American-made technology system will be used for the prototype of vehicles for government entities EUGENE, Ore., Aug. 21, 2023 (GLOBE NEWSWIRE) — Arcimoto, Inc.® (NASDAQ: FUV), makers of rightsized, ultra-efficient small footprint electric vehicles for moving people and things, today announced a partnership with MATBOCK, a veteran-owned business that designs and builds hybrid-electric tactical vehicles and innovative tactical gear, to supply the company with electrical systems architecture and energy storage systems for the development of hybrid-electric tactical vehicles. The partnership will allow MATBOCK to maintain its focus on paradigm-shifting technology by providing American-made technologies to be used by the U.S. Department of Defense in specific areas of operations. In 2022, MATBOCK launched its tactical electric vehicle...

Figure 1LAC 50 Mineralized Trend on the LUR Angilak Property, Nunavut. Yellow star indicates Main Zone drilling area.TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) — Latitude Uranium Inc. (“Latitude Uranium”, “LUR” or the “Company”) (CSE: LUR, OTCQB: LURAF, FRA: EI1) is pleased to provide an update to shareholders in an open letter from President and CEO John Jentz. Dear Shareholders, Throughout the past year, Latitude has solidified its position as a Canadian uranium explorer and developer. With the resurgence in the nuclear sector, I am pleased to share an update on the steps we are taking to position Latitude for future success. I would also like to extend a formal welcome to our new shareholders from Valore Metals Corp (TSXV: VO). Transformative Restructuring to Latitude – Diversified and Derisked I joined Latitude Uranium...

Phase 1/2 Clinical Trial of TNX-801 for the Prevention of Mpox and Smallpox to Commence Following Submission of an IND TNX-801 is Based on a Proprietary Live Virus Vaccine Platform Designed to Stimulate Durable T-Cell Immunity TNX-801 Vaccination Protected Animals from a Lethal Challenge with Monkeypox in Preclinical Testing CHATHAM, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) —  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it received the official written response from a Type B pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-8011 (recombinant horsepox virus, live vaccine) as a potential vaccine to protect against mpox disease...